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Summary Bombesins are potent growth factors for murine Swiss 3T3 cells. Using these cells in chemically
defined conditions we have been able to characterise the bombesin receptor and the early signals preceding
DNA synthesis. We describe two substance P analogues [DArg1, DPro2, DTrp7 9, Leu1 ] substance P and
[DArg1, DPhe5, DTrp7 9, Leu1'] substance P which competitively block the binding of bombesins to their
receptor and all the events leading to mitogenesis. Bombesins are secreted by human small cell lung cancers
(SCLC) and may act as autocrine growth factors for these tumours, so the development of peptide bombesin
antagonists could have therapeutic implications. We demonstrate that the antagonists can reversibly inhibit
the growth of SCLC in vitro, with relatively little effect on other lung tumours.
Growth factors are implicated in a wide variety of
physiological and pathological processes including
embryogenesis, haemopoiesis, wound healing, immune
responses, atherosclerosis and neoplasia (Evered et al., 1985;
Sporn & Roberts, 1986). An important link between growth
factors and their receptors and oncogene products has also
been established (Heldin & Westermark, 1984; Weinstein,
1987). Thus, the elucidation of the mechanism of action of
growth factors has emerged as one of the fundamental
problems in biology and may prove crucial for under-
standing the unrestrained proliferation of cancer cells.
Many studies of growth factors have used cultured
fibroblasts, such as 3T3 cells, as a model system. These cells
cease to proliferate when they deplete the medium of its
growth promoting activity. Such quiescent cells can be
stimulated to reinitiate DNA synthesis and cell division
either by replenishing the medium with fresh serum, or by
the addition of growth factors or pharmacological agents in
serum-free medium (Rozengurt, 1983) (Figure 1). Studies
performed with combinations of growth factors have
revealed an important aspect of their action: the existence of
potent and specific synergistic interactions (Rozengurt,
1986). This finding suggested that growth factors bind to
different receptors, and generate multiple intracellular signals
which interact synergistically to initiate a proliferative
response.
A new and intriguing development is the discovery that
neuropeptides such as bombesin, vasopressin, vasoactive
intestinal peptide (VIP), and substance K (Zachary et al.,
1987b) can also act as growth factors for cells in culture
(Figure 1). Bombesin-like peptides are potent mitogens for
Swiss 3T3 cells (Rozengurt & Sinnett-Smith, 1983) and have
attracted interest as possible autocrine growth factors for
small cell lung cancer (SCLC). Here we summarize our
recent studies using bombesin-like peptides for elucidating
the signal transduction pathways leading to mitogenesis and
lung bombesin antagonists in SCLC.
Bombesin
Bombesin is a tetradecapeptide first isolated from amphibian
skin (Anastasi et al., 1971). Struct-urally-related peptides
(Table I) in amphibians and mammals are widely distributed,
but found notably in the gut (e.g. gastrin-releasing peptide
GRP) where they have secretory effects (McDonald et al.,
1979; Lezoche et al., 1981) and central nervous system (eg
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Figure 1 Growth factors, neuropeptides and various
pharmacological agents can stimulate mitogenesis in quiescent
Swiss 3T3 cells.
the neuromedins) where they may act as neurotransmitters
(Minamino et al., 1983; 1984; 1985).
Bombesin-like peptides are abundant in fetal lung
(Wharton et al., 1978; Price et al., 1983; Yamaguchi et al.,
1983) and the mRNA for GRP is maximally expressed at
16-30 weeks (Spindel et al., 1987). Thereafter levels decline
rapidly, and in adulthood these peptides are found sparsely
in bronchial neuroendocrine cells. Speculation that
bombesins may be growth factors for fetal lung has been
supported by the paucity of expression in the immature
lungs of infants with respiratory distress syndrome (Ghatei et
al., 1983).
Mitogenic response of Swiss 3T3 cells to bombesin
In serum-free medium, bombesin induces DNA synthesis and
cell division in the absence of other growth-promoting agents
with a half-maximal effect at 1 nM. The ability of bombesin,
like-platelet-derived growth factors (PDGF), to act as a sole
mitogen for Swiss 3T3 cells contrasts with other growth
factors which are only active in synergistic combinations
(Rozengurt, 1986). The stimulation of DNA synthesis by
bombesin is markedly potentiated by insulin. This hormone,
probably acting in lieu of insulin-like growth factor-I
(IGF1), both increases the maximal response elicited by
Correspondence: E. Rozengurt.
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Table I Amino acid sequences of bombesin-like peptides
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Thr Val Leu Thr Lys-
Trp Ala Val Gly His Leu Met -NH2
Thr Val Leu Ala Lys-
Trp Ala Val Gly His Leu Met -NH2
Trp Ala Val Gly His Leu Met -NH2
Trp Ala Val Gly His Leu Met -NH2
Trp Ala Thr Gly His Phe Met -NH2
Trp Ala Val Gly His Leu Met -NH2
Trp Ala Val Gly His Leu Met -NH2
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bombesin and decreases the bombesin concentration required
to produce a half-maximal response (from 1 nM to 0.3nM).
Other bombesin-like peptides including GRP behave
similarly in the stimulation of DNA synthesis (Zachary &
Rozengurt, 1985a).
Specific bombesin receptors in Swiss 3T3 cells
To establish the presence of specific receptors for bombesin
in Swiss 3T3 cells we used radioiodinated [1251]GRP. This
binds to the intact, quiescent cells in a specific, saturable and
reversible manner (Zachary & Rozengurt, 1985a). Scatchard
analysis indicates the presence of a single class of high-
affinity sites of Kd -1 nM and - 1.25 x 105 binding sites per
cell. [125I]GRP binding was not inhibited by other mitogens
for Swiss 3T3 cells including PDGF, fibroblast derived
growth factor (FDGF), epidermal growth factor (EGF),
vasopressin, phorbol 12,13, dibutyrate (PBt2), insulin and two
neuropeptides, VIP and substance P (Zachary & Rozengurt,
1985a). [125I]GRP binding was inhibited by other bombesin-
like peptides in proportion to their ability to stimulate DNA
synthesis. These results strongly suggest that bombesins
interact with receptors that are distinct from those for other
mitogens in Swiss 3T3 cells.
Physicalproperties ofthe bombesin receptor
To investigate the physical properties of the bombesin/GRP
receptor, we used an affinity-labelling method to identify
surface components of Swiss 3T3 cells which specifically
recognize [1251]GRP. Analysis of extracts of cells which had
been preincubated with [125I]GRP and then treated with
disuccinimidyl cross-linking agents revealed the presence of a
major band migrating with apparent M, 75,000-85,000
(Zachary & Rozengurt, 1987a).
Several lines of evidence support the conclusion that this
protein is a component of the bombesin receptor: (1) the Mr
75,000-85,000 protein was not found in other cell lines which
do not exhibit receptors for bombesin-like peptides; (2) The
inhibition of [125I]GRP affinity-labelling of this band with
unlabelled GRP corresponded closely with the ability of
GRP to inhibit the binding of the labelled ligand in a
parallel set of cultures. Other bombesin-like peptides also
inhibited the cross-linking of [125I]GRP to this component
in a dose-dependent manner; (3) [125I]GRP affinity-labelling
of the M. 75,000-85,000 band was unaffected by other
mitogens and peptide hormones; (4) the dependence of
affinity-labelling of the M, 75,000-85,000 protein on the
concentration of [125I]GRP closely paralleled the ability of
unlabelled GRP to stimulate DNA synthesis and a variety of
other biological responses in Swiss 3T3 cells.
A solubilized preparation of the radiolabelled Mr 75,000-
85,000 protein binds to wheatgerm lectin-sepharose columns
and can be eluted with N-acetyl-D-glucosamine, suggesting
that it is a glycoprotein. In addition, treatment with endo-fl-
N-acetyl glycosaminidase F reduced the apparent molecular
weight of the affinity-labelled band from 75,000-85,000 to
42,000, indicating the presence of N-linked oligosaccharide
groups (Sinnett-Smith, Zachary & Rozengurt, unpublished
results). These findings would be consistent with a receptor
of the type recently described for substance K (Masu et al.,
1987).
Bombesin does not cause down-regulation ofits receptor
The binding of polypeptide growth factors such as EGF and
PDGF to their receptors is followed by rapid internalization
and intracellular degradation of the ligand and the receptor
(James & Bradshaw, 1984; Goldstein et al., 1985). This
process results in a marked reduction in the number of
surface binding sites in the target cells (down-regulation). In
contrast, exposure of Swiss 3T3 cells to mitogenic concen-
trations of bombesins for different times up to 24h did not
cause any significant change in the number of cell surface
binding sites for these peptides (Zachary & Rozengurt,
1987b). Furthermore, pretreatment with GRP did not cause
either an alteration in the concentration dependence of
binding of the labelled peptide or a reduction in the level of
the Mr 75,000-85,000 surface protein component of the
bombesin receptor.
It has been proposed that the internalisation and
degradation of growth factor receptors and their ligands may
have a signalling function in mitogenesis (King &
Cuatrecasas, 1981; James & Bradshaw, 1984; Bergeron et al.,
1985; Wakshull & Wharton, 1985). The fact that the
bombesins are able to stimulate DNA synthesis and trigger a
wide variety of signalling events without reducing the
number of their surface receptors suggests that extensive
receptor down-regulation is not always an obligatory process
in mitogenesis.
Early events elicited by bombesins
The binding of growth factors to their receptors promotes
the generation of early signals in the membrane, cytosol and
nucleus which lead to cell proliferation (Rozengurt, 1986).
Since the initiation of DNA synthesis occurs 10 to 15h after
the addition of the mitogens, it is expected that knowledge
of the early events will provide clues to primary regulatory
mechanisms. These are summarized in Figure 2.
Ionfluxes
One of the earliest events to occur after the binding of
various mitogens to their receptors is an increase in theBOMBESIN AND ANTAGONISTS 581
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Figure 2 Early events elicited by bombesin in quiescent Swiss
3T3 cells.
fluxes of Na+, K+ and H+ across the plasma membrane.
Bombesins stimulate a rapid influx of Na+ into Swiss 3T3
cells via an amiloride-sensitive Na+/H+ antiport (Mendoza
et al., 1986). This increases intracellular Na+ and causes
cytoplasmic alkalinization. Since the activity of the Na+/K+
pump is regulated by intracellular Na+, there is a secondary
stimulation of Na+/K+ pump activity which increases K+
and restores the electrochemical gradient for Na+. The
ability of bombesin, like PDGF and other growth factors, to
induce cytoplasmic alkalinization suggests that the activation
of Na+/H+ exchange is a primary effect of the mitogens
rather than a compensatory mechanism for the extrusion of
protons resulting from a growth factor-induced acceleration
of cellular metabolism.
In addition to rapid changes in monovalent ion fluxes,
bombesins cause a rapid mobilization of Ca2+ from intra-
cellular stores, which leads to a transient increase in the
concentration of cytosolic Ca2` (Mendoza et al., 1986). This
Ca2+ flux is distinct from that caused by PDGF (Lopez-
Rivas et al., 1987). The mobilization of Ca2` by bombesins
and other mitogens may be mediated by inositol 1,4,5-
trisphosphate (IP3), which has been proposed to act as a
second messenger in the action of many ligands that
stimulate phospholipase C-mediated inositol lipid turnover
and Ca2` efflux (Berridge & Irvine, 1984). IP3 is formed as
a result of phospholipase C catalysed hydrolysis of
phosphatidyl 4,5-bisphosphate (PIP2) in the plasma
membrane, a process that also generates 1,2-diacylglycerol
(DAG). Bombesins have been shown to cause enhanced
inositol lipid metabolism in Swiss 3T3 cells leading to the
formation of 1P3 (Heslop et al., 1985; Lopez-Rivas et al.,
1987; Muir & Murray, 1987; Takuwa et al., 1987).
Activation ofprotein kinase C
Protein kinase C (which is stimulated by DAG) has received
considerable attention because it is a major receptor for the
tumour promoters of the phorbol ester family (Nishizuka,
1984). Since phorbol esters and 1-oleoyl-2-acetylglycerol
(OAG) can act as mitogens for quiescent cells, protein kinase
C may play a role in the initiation of a proliferative response
(Dicker & Rozengurt, 1980; Rozengurt et al., 1984). The M,
80,000 cellular protein termed 80K has been shown to be a
specific substrate of protein kinase C in intact cultured cells
(Rozengurt et al., 1983; Bishop et al., 1985; Blackshear et al.,
1985; 1986; Rodriguez-Pena & Rozengurt, 1986). Although
the nature and role of the 80K protein remain obscure,
changes in its phosphorylation state provide a marker for
protein kinase C activation in intact cells (Figure 2).
Addition of bombesins causes a rapid (15 seconds)
increase in 80K phosphorylation in quiescent Swiss 3T3
cells (Isacke et al., 1986; Zachary et al., 1986). Removal of
the peptide results in rapid (half-life 90s) dephosphorylation
of 80K. Prolonged. pretreatment (40h) with PBt2 leads to
the disappearance of measurable protein kinase C activity
and prevents the increase in 80K phosphorylation by
subsequent addition of phorbol esters, phospholipase C, or
OAG (Rodriguez-Pena & Rozengurt, 1984; Ballaster &
Rosen, 1985; Stabel et al., 1987). This treatment completely
abolished the effect of bombesin on 80K phosphorylation
(Zachary et al., 1986). The stimulation of protein kinase C
may play an important role in mediating the proliferative
response elicited by bombesins in Swiss 3T3 cells. In support
of this, bombesin stimulation of DNA synthesis is abolished
by long-term exposure to phorbol esters (Rozengurt &
Sinnett-Smith, 1987). This inhibition can, however, be fully
reversed by insulin. Thus, activation of protein kinase C
represents one of the pathways through which bombesins
can initiate cell proliferation. A number of growth factor
receptors and retroviral oncogene products exhibit tyrosine-
specific protein kinase activity. Whether or not bombesin
stimulates tyrosine phosphorylation remains controversial
(Isacke et al., 1986; Cirillo et al., 1986).
Protein kinase C, ionfluxes and transmodulation ofEGF
receptor
In addition to its role in stimulating cell division, protein
kinase C may also be important in coordinating the network
of early events triggered by bombesins. Activation of protein
kinase C leads to increased activity of the Na+/H+ antiport
system (Vara et al., 1985). Stimulation of ion fluxes by
bombesins is only partially inhibited, however, by PBt2
pretreatment suggesting that these peptides can stimulate
Na+/H+ antiport activity by an alternative mechanism
(dotted line, Figure 2) (Mendoza et al., 1986). Protein kinase
C activation can also inhibit Ca2+ mobilization, suggesting
some feedback control (Lopez-Rivas et al., 1987).
[125I]EGF binding to specific surface receptors in Swiss
3T3 cells is markedly inhibited by bombesins (Brown et al.,
1984; Zachary et al., 1986). The effect is rapid in onset and
results from a decrease in the apparent affinity of the EGF
receptor population for EGF. Considerable evidence
implicates protein kinase C in the regulation of EGF
receptor affinity by bombesin and other transmodulating
agents (Zachary & Rozengurt, 1985b): the inhibition of EGF
binding induced by either PBt2 or bombesin is prevented by
the removal of protein kinase C from the cells by prolonged
treatment with phorbol esters; the EGF receptor is
phosphorylated by protein kinase C at a specific site (Thr
654) both in vitro and in vivo (Lin et al., 1986). Thus,
transmodulation of the EGF receptor may result from the
covalent modification of the EGF receptor catalysed by
protein kinase C, though other mechanisms are not excluded.
Cyclic nucleotides
A sustained increase in the intracellular level of cyclic AMP
(cAMP) can act as a mitogenic signal for many cell types
(Rozengurt, 1986). Activation of protein kinase C either
directly by PBt2 or by vasopressin (through receptors which
are not directly coupled to adenylate cyclase), has recently
been shown to enhance cAMP accumulation in Swiss 3T3
cells (Rozengurt et al., 1987). We have found that bombesin
also markedly potentiates the accumulation of cAMP caused
by cAMP-elevating agents such as forskolin, an effect
mediated at least in part by protein kinase C (Millar &
Rozengurt, unpublished results).
Induction ofthe proto-oncogenes c-fos and c-myc
Like PDGF and other growth factors, bombesins rapidly
and transiently induce the expression of the cellular
oncogenes c-fos and c-myc (Letterio et al., 1986; Palumbo et
al., 1986; Rozengurt & Sinnett-Smith, 1987). Enhanced
expression of c-fos occurs within minutes of bombesin
addition and is followed by increased expression of c-myc.582 P.J. WOLL & E. ROZENGURT
The time-course and magnitude of these effects are similar to
those induced by a saturating concentration of PDGF.
Bombesin-induced oncogene expression is markedly
reduced by densitization of the protein kinase C pathway,
implicating the activation of this phosphotransferase in the
sequence of events leading to increased oncogene expression.
However, because bombesin causes a marked increase in
cytosolic Ca2+ and since elevation of Ca2+ by addition of
the Ca2 + ionophore A23187 enhances c-fos and c-myc
induction by PBt2, it is likely that the induction of these
cellular oncogenes by bombesin is mediated by the
coordinated effects of Ca2+ mobilization and activation of
protein kinase C (Figure 2) (Rozengurt & Sinnett-Smith,
1987). However, additional signalling pathways may exist.
Effect ofpertussis toxin
In many cell types, pertussis toxin (which ADP-ribosylates
and inactivates guanine nucleotide regulatory proteins) inter-
feres with the receptor-mediated cleavage of PIP2 thereby
inhibiting the production of IP3 and DAG. Letterio et al.
(1986) reported that pertussis toxin blocks bombesin stimula-
tion of DNA synthesis and induction of c-myc expression, an
effect mediated at least in part by activation of protein
kinase C. It was s-uggested that the bombesin receptor might
be coupled to phospholipase C by a pertussis toxin-sensitive
G protein. Recent experiments from our laboratory do not
support this hypothesis. While pertussis toxin selectively
inhibited bombesin-stimulated mitogenesis at an early stage
in the action of the peptide, the toxin did not interfere with
polyphosphoinositide breakdown, Ca2 + mobilization or
activation of protein kinase C (Zachary et al., 1987a). We
therefore concluded that the pertussis toxin-sensitive step in
the stimulation of mitogenesis by bombesin and structurally
related peptides can be dissociated from the phospholipase C
signalling pathway.
Bombesin and lung cancer
Lung cancer is the commonest fatal malignancy in the
developed world and its incidence is increasing (Bailar &
Smith, 1986). SCLC constitutes 25% of these; it follows an
aggressive course and, despite being initially chemosensitive,
only 5% of patients survive 2 years after diagnosis (Spiro,
1985). These tumours are associated with ectopic production
of many different hormones, including vasopressin, adreno-
corticotropin (ACTH) and bombesin. High concentrations of
bombesins are present in specimens of SCLC and are-
secreted by SCLC cell lines in vitro (Moody et al., 1981;
Wood et al., 1981; Erisman et al., 1982). The mRNA for
GRP has been demonstrated in SCLC using synthetic
oligodeoxyribonucleotide probes, and correlates well with
immunoreactive GRP (Suzuki et al., 1987). Cloned cDNAs
to preproGRP have been prepared from SCLC and
pulmonary carcinoid tumours but not other lung tumours.
The mRNA for preproGRP encodes a single copy of the
GRP molecule and a 95 amino acid carboxy-terminal
extension peptide, the actions of which are unknown
(Spindel et al., 1984; Sausville et al., 1986; Lebacq-
Verheyden et al., 1987).
In view of the potent mitogenic activity of bombesins in
the Swiss 3T3 model system, we suggested that secretion of
these neuropeptides by SCLC could constitute part of an
autocrine growth circuit (Rozengurt & Sinnett-Smith, 1983).
Bombesins are reported to stimulate SCLC grown in vitro
(Weber et al., 1985; Carney et al., 1987). Cuttitta et al.
(1985) demonstrated that monoclonal antibodies to
bombesin inhibited the clonal growth of two SCLC cell lines
in vitro and the growth of one of the lines as xenografts in
nude mice. These findings strengthened the hypothesis of
autocrine growth stimulation by bombesins in SCLC.
Bombesin antagonists
If bombesins are important in sustaining the unrestrained
proliferation of SCLC, then the interruption of the putative
autocrine growth loop with bombesin antagonists should
suppress the growth of this tumour. An antagonist must
bind to the specific receptor without producing the confor-
mational changes which trigger the biological response.
Antagonists to neurotransmitters (such as acetylcholine), a-
and fl-adrenoceptors and histamines have had a large impact
on clinical medicine, and synthetic peptide antagonists to
parathyroid hormone and glucagon are under development
(Rosenblatt, 1986). Potent and specific bombesin antagonists
could be crucial for testing the hypothesis of autocrine
growth stimulation in SCLC.
[DArg',DPro2 DTrp7'9,Leu1 1] substance P
The tachykinin substance P has minimal structural homology
with bombesin (Table II) and neither inhibits the binding of
[125I]GRP nor stimulates DNA synthesis in Swiss 3T3 cells.
Unexpectedly, the substance P antagonist [DArg', DPro2,
DTrp7'9, Leu' ] substance P (Peptide A in Table II) was
found to block the secretory effects of bombesin in
pancreatic acinar cells (Jensen et al., 1984) and it was
subsequently shown to antagonise the growth-promoting
effects of bombesin in Swiss 3T3 cells (Zachary &
Rozengurt, 1985a). It has now been shown to block all the
early events leading to bombesin-stimulated mitogenesis in
these cells (Table III). It also inhibits mitogenesis stimulated
by vasopressin (Corps et al., 1985; Zachary & Rozengurt,
1986).
SCLC cell lines grown in serum-free medium achieve 10-
fold increase in number in about 12 days. Figure 3 (left)
shows that the growth of H69 cells was suppressed by
peptide A at 150 pM (a concentration that reversibly inhibits
GRP-induced mitogenesis in Swiss 3T3 cells) but restored by
Table U Amino acid sequences of bombesin, substance P and the substance P antagonists tested as inhibitors of GRP-stimulated DNA synthesis
Bombesin pGlu Gin Arg Leu Gly Asn Gin Trp Ala Val Gly His Leu Met NH2
1 2 3 4 5 6 7 8 9 10 11
tance P Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met NH2
Lgonist | A DArg Dpro Lys Pro Gln Gln DTrp Phe DTrp Leu Leu NH2
B DArg Pro Lys Pro Gln Gln DTrp Phe DTrp Leu Leu NH2
C Arg DPro Lys Pro Gln Gln DPhe Phe DTrp Leu Met NH2
|D DArg Pro Lys Pro DPhe Gln DTrp Phe DTrp Leu Leu NH2
E Arg DPro Lys Pro Gln Gln DTrp Phe DTrp Leu Met NH2
F DPro Gln Gln DTrp Phe DTrp DTrp Met NH2
G Arg DTrp MePhe DTrp Leu Met NH2
H DArg DPro Lys Pro Gin Gln *DPhe -Phe 4-DHis Lbeu Mets NH2
J HArg Gly Gln DTrp Phe Gly Asp (OtBu)2
K DPro Gln Gln DTrp Phe DTrp Leu Met NH2BOMBESIN AND ANTAGONISTS 583
Table III Effects of [DArg', DPro2, DTrp7 9, Leu"1] substance P in Swiss 3T3 cells
[DArg', DPro2, DTrp7 9, Leu"1] substance P reversibly blocks:
Reference
[125I] GRP binding 1
Cross-linking of [1251I] GRP to the Mr 75,000-85,000 glycoprotein 2
80K phosphorylation 3
EGF transmodulation 3
Ca2+ mobilization 4
Activation of Na+/K+ pump 4
Increase in c-fos and c-myc expression 5
Stimulation of DNA synthesis by bombesin-like peptides 1
Stimulation of DNA synthesis by vasopressin 6,7
DNA synthesis stimulated by PDGF, EGF, phorbol esters and
c-AMP-increasing agents is not affected I
References: 1, Zachary & Rozengurt, 1985a; 2, Zachary & Rozengurt, 1987a; 3,
Zachary et al., 1986; 4, Mendoza et al., 1986; 5, Rozengurt & Sinnett-Smith, 1987; 6,
Zachary & Rozengurt, 1986; 7, Corps et al., 1985.
washing the cells and re-suspending them in serum-free
medium. Figure 3 (right) demonstrates that the effect of the
antagonist is concentration dependent. These results suggest
a specific, non-toxic effect.
[DArg1, DPhe5, DTrp7 9,Leut1] substance P
In order to identify more potent bombesin antagonists we
have tested ten substance P antagonists at 50/iM (Table II)
for their ability to inhibit GRP-stimulated mitogenesis in
Swiss 3T3 cells. [DArg', DPhe5, DTrp7'9, Leu'1] substance
P (Peptide D in Table II) was clearly the most potent GRP
antagonist. None of the other peptides was superior to
peptide A but peptide D was consistently 5-fold more
potent. None of these peptides exhibited agonist activity.
Clearly the substitution of DPhe for Gln at position 5 is
critical to the enhanced activity of peptide D.
Detailed studies of peptide D have now been completed
(Woll & Rozengurt, 1988). Its effects on the dose-response
curve for GRP in an assay of DNA synthesis is shown in
Figure 4 (left). The dose-response curve is shifted to the right
but retains its shape, indicating that the effect of the
antagonist is competitive and reversible. The dose-response
curve for peptide D in the presence of GRP 3.6nM is shown
in figure 4 (right). Half-maximal inhibition of DNA
synthesis was obtained with 22yM antagonist.
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Figure 3, Left: [DArg', DPro2, DTrp7 9, Leu1 ] substance P
(peptide A in Table II) reversibly inhibits the growth of the H69
SCLC cell line. Cells were incubated in HITES medium (Carney
et al., 1981) supplemented with 0.25% bovine serum albumin in
the absence (0) or presence (0) of peptide A 150gm. Additional
samples (Ol) were preincubated with 150 LM peptide A and
resuspended in medium without antagonist. All samples were
plated on day 0 with an inoculum of 5 x 104 cells. Cell number
was determined using a Coulter counter. Each point represents
the mean of 3 determinations. Right: Peptide A inhibits the
growth of H69 cells in a concentration-dependent manner. Cells
inoculated at 5 x 104Mml- were incubated in serum-free medium
(as above) containing varying concentrations of peptide A. Cells
were counted on day 13. Each point represents the mean (± s.d.)
of 5 determinations.
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Figure 4, Left: Stimulation of DNA synthesis by GRP in
quiescent Swiss 3T3 cells in the absence (-) or presence (A) of
peptide D 40pM. Cells were incubated in Dulbecco's modified
Eagle's/Waymouth medium (DMEWM) containing [3H]
thymidine 1 MCiml-1 and insulin 1 jugml-'. DNA synthesis was
assessed after 40h by [3H]thymidine incorporation into acid-
insoluble material (Dicker & Rozengurt, 1980; Rozengurt &
Sinnett-Smith, 1983). Right: Effects of varying concentrations of
peptide D on DNA synthesis in the presence of 3.6nM GRP and
insulin I jigml-1.
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Figure 5, Left: Stimulation of DNA synthesis by vasopressin in
quiescent Swiss 3T3 cells in the absence (-) or presence (A) of
peptide D 20!M. Cells were incubated in DMEWM with [3H]
thymidine pCiml-' and insulin pgml-'. DNA synthesis was
assessed after 40h by [3H] thymidine incorporation into acid
insoluble material (as in Figure 4). Right: Effects of varying
concentrations of peptide D on DNA synthesis in the presence of
14nm vasopressin and insulin pgml- 1.
Like peptide A, peptide D exhibits specificity in blocking
mitogenesis. It does not interfere with DNA synthesis
stimulated by PBt2, cholera toxin with isobutylmethyl-
xanthine, EGF or PDGF. Vasopressin-stimulated DNA
synthesis, however, is markedly inhibited in a competitive
and reversible manner (Figure 5). Thus peptide D is an
antagonist for at least three distinct neuropeptides whose
effects are mediated through specific receptors.
Binding of [125I]GRP to the bombesin/GRP receptor in
Swiss 3T3 cells is not inhibited by vasopressin or substance
P. In contrast, peptide D inhibits [1251]GRP binding in a
dose-dependent manner (Figure 6, left) which is half-
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Figure 6, Left: Inhibition of [125I] GRP binding to Swiss 3T3
cells by peptide D. Quiescent cells were incubated with 1 nM
[125I] GRP and varying amounts ofpeptide D for 30min (Zachary)
& Rozengurt, 1985a). Binding is expressed as percentage of the
specific binding obtained in the absence of antagonist. Right:
Effects of peptide D on affinity labelling of bombesin receptor-
associated M, 75,000-85,000 protein. Confluent Swiss 3T3 cells
were incubated for 2h in binding medium containing 0.5nM
[125I] GRP and varying amounts of peptide D. After washing,
they were incubated for 15min with the cross-linking agent
ethylene glycol bis (succinimidyl succinate) then solubilized and
electrophoresed on a 10% polyacrylamide gel (inset) (Zachary &
Rozengurt, 1987a). Results are expressed as percentage of the
control on scanning densitometry of the autoradiographs.
maximal at 2.3pM. Cross-linking of the Mr 75,000-85,000
protein component of the bombesin/GRP receptor is
inhibited by peptide D with half-maximal effect at 5.5pM
(Figure 6, right). These findings indicate that the effects of
peptide D on mitogenesis stimulated by the bombesins are
mediated through the specific bombesin receptor.
Peptide D inhibits the growth of SCLC cell lines in vitro
with half-maximal effect at 24pM in the H69 cell line (Woll
& Rozengurt, 1988). As in the Swiss 3T3 system, the new
antagonist is 5-fold more potent than peptide A. The
effects on non-small cell lung cancer (NSCLC) cell lines are
less striking. Figure 7 contrasts the effects of the new
antagonist at 404uM on growth in chemically defined medium
supplemented with 1% serum of the H128 SCLC line and
two NSCLC lines, sk-mes-1 (squamous) and sk-lu-1 (adeno-
carcinoma). Although the NSCLC lines do not grow as
readily as SCLC line in vitro, the antagonist has much less
inhibitory effect on them than on the SCLC line.
Conclusion
The use of the Swiss 3T3 murine fibroblast system in
chemically defined conditions has allowed comprehensive
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Figure 7 Effects of peptide D on proliferation of SCLC and
NSCLC cell lines. Cells were incubated in HITES medium
supplemented with 0.25% albumin and 1% fetal bovine serum
in the absence (El) or presence (-) of peptide D 40pM. Cell
number was determined when maximal growth had been
achieved, at Day 11 for H128 and at Day 7 for sk-mes-l and
sk-lu-1. Results are expressed as the mean (±s.d.) of 5
determinations.
investigation into the mechanism of action of bombesins as
mitogens. Detailed knowledge of these growth-regulatory
pathways has led to formulation of hypotheses concerning
the control of tumour growth in SCLC. These hypotheses
will be subject to critical testing using synthetic bombesin
antagonists such as [DArg', DPhe5, DTrp7'9, Leu11] sub-
stance P. Although this antagonist profoundly inhibits the
growth of SCLC in vitro, it is not yet clear whether this
effect is mediated through bombesin alone or other neuro-
peptide growth factors. Both [DArg1, DPro2, DTrp7'9,
Leu11] substance P and [DArg1, DPhe5, DTrp7 9, Leu11]
substance P antagonise the effects of three neuropeptides,
bombesin, vasopressin and substance P through their distinct
receptors. It is tempting to speculate that these antagonists
could bind to a common domain in the three receptors. A
possible model for this is provided by the recent molecular
cloning of a receptor for the neuropeptide substance K,
which has seven transmembrane segments and shows amino
acid sequence homology with other neurotransmitter recep-
tors and with the mas human oncogene (Hanley & Jackson,
1987; Masu et al., 1987). More potent and specific bombesin
antagonists could prove useful as investigative tools and
potential therapeutic agents with high tissue penetration.
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